ImpriMed
AI-driven personalized medicine for veterinary and human cancer care
ImpriMed is transforming both veterinary and human oncology with its cutting-edge AI-driven precision medicine approach. ImpriMed's innovative AI models leverage live cancer cell analytics to enable oncologists to make precise, data-driven treatment decisions tailored to individual patients. With proven success in over 10,000 cases in dogs and cats, the company is now expanding into human cancer treatment. Additionally, the live-cell-based drug efficacy assessment platform offers pharmaceutical companies an invaluable tool to pretest drug compounds on their target patients' live cells, enhancing clinical trial success rates and streamlining market entry.
Testimonial
Related Companies
GenProof
GenProof generates mathematical proofs that guarantee 100% code correctness
San Francisco, California, United States
Klona Biotech
The future of human tissue replacements using 3D printing
London, United Kingdom
Glīd
Autonomous dual-mode vehicles that seamlessly transition between road and rail to deliver faster, greener, and more resilient first-mile logistics
Shaver Lake, CA
Lyric Bio
Pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies
San Carlos, California
Autolane
The platform orchestrating autonomous vehicles for commerce and ride-hailing
United States
Eywa Biotech
Scaling the production of pharmaceutical-grade psychedelic compounds through synthetic biology
Montevideo, Uruguay · Buenos Aires, Argentina
NLPatent
AI-native patent research and intelligence platform purpose-built to overcome the limitations of traditional patent research.
Toronto, Ontario, Canada
